Seely Lynn — SEC Form 4 filings
SEC reporting owner CIK 1327111. 16 Form 4 filings on record with FilingPulse; latest filed 2026-08-25.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2024-02-13 to 2026-08-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 175,000 shares, $106,190 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 9 legs across 8 filings — 26,726 shares, $437,910 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: sale of 7,455 shares @ $23.39 ($174,372) in Lyell Immunopharma, Inc., filed 2026-02-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | President and CEO, Director | 12 | 1 leg · 175,000 sh · $106,190 | 9 legs · 26,726 sh · $437,910 | 8 |
| Blueprint Medicines Corp (BPMC) | Director | 3 | — | — | 15 |
| AbCellera Biologics Inc. (ABCL) | Director | 1 | — | — | 1 |
Form 4 filings — Seely Lynn
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-25 | 4 | Lyell Immunopharma, Inc. (LYEL) | Sale (S): 9,589 @ $15.54 | EDGAR |
| 2026-08-11 | 4 | Lyell Immunopharma, Inc. (LYEL) | Sale (S): 390 @ $14.34 | EDGAR |
| 2026-07-06 | 4 | AbCellera Biologics Inc. (ABCL) | Grant/award (A): 152,207 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Lyell Immunopharma, Inc. (LYEL) | Sale (S): 388 @ $18.91 | EDGAR |
| 2026-02-12 | 4 | Lyell Immunopharma, Inc. (LYEL) | Sale (S): 7,455 @ $23.39 | EDGAR |
| 2026-02-11 | 4 | Lyell Immunopharma, Inc. (LYEL) | Grant/award (A): 20,000 @ $0 · Sale (S): 438 @ $23.12 · Grant/award (A): 155,000 (derivative) @ $0 | EDGAR |
| 2025-11-12 | 4 | Lyell Immunopharma, Inc. (LYEL) | Sale (S): 412 @ $16.11 | EDGAR |
| 2025-10-29 | 4 | Lyell Immunopharma, Inc. (LYEL) | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-08-22 | 4 | Lyell Immunopharma, Inc. (LYEL) | Grant/award (A): 40,000 @ $0 · Sale (S): 7,257 @ $10.54 | EDGAR |
| 2025-08-13 | 4 | Lyell Immunopharma, Inc. (LYEL) | Sale (S): 391 @ $10.53 · Sale (S): 406 @ $10.34 | EDGAR |
| 2025-07-21 | 4 | Blueprint Medicines Corp (BPMC) | Disposition to issuer (D): 3,902 · Code (U): 13,254 · Disposition to issuer (D): 21,818 (derivative) · Disposition to issuer (D): 10,909 (derivative) · Disposition to issuer (D): 10,909 (derivative) · Disposition to issuer (D): 7,500 (derivative) · +6 more | EDGAR |
| 2025-06-24 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 3,902 @ $128.12 | EDGAR |
| 2025-03-18 | 4 | Lyell Immunopharma, Inc. (LYEL) | Purchase (P): 175,000 @ $0.61 | EDGAR |
| 2025-02-26 | 4 | Lyell Immunopharma, Inc. (LYEL) | Grant/award (A): 337,500 @ $0 · Grant/award (A): 1,350,000 (derivative) @ $0 · Grant/award (A): 168,750 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Blueprint Medicines Corp (BPMC) | Grant/award (A): 2,242 @ $0 · Grant/award (A): 4,570 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | Lyell Immunopharma, Inc. (LYEL) | Grant/award (A): 200,000 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1327111 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →